Clopidogrel–Statin Interaction Myth or Reality?⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology. by Angiolillo, Dominick J. & Alfonso, Fernando
C
M
D
F
J
V
e
b
“
(
l
m
p
H
a
s
c
h
(
S
i
c
a
a
c
C
t
r
a
P
C
(
i
a
f
C
s
v
C
I
d
p
o
q
a
m
o
n
c
c
C
s
t
a
m
I
l
s
e
(
h
w
p
a
i
e
a
r
(
fi
c
m
o
a
s
(
C
fi
C
C
t
a
p
s
i
a
b
t
*
v
A
J
v
b
Journal of the American College of Cardiology Vol. 50, No. 4, 2007
© 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2007.04.041EDITORIAL COMMENT
lopidogrel–Statin Interaction
yth or Reality?*
ominick J. Angiolillo, MD, PHD, FACC, FESC,†
ernando Alfonso, MD, PHD, FESC‡
acksonville, Florida; and Madrid, Spain
ariability in individual responsiveness to clopidogrel is an
merging clinical problem (1). Numerous mechanisms have
een implied in this phenomenon, among which a
clopidogrel–statin interaction” has been highly speculated
1–4). In particular, lipophilic statins, which are metabo-
ized by cytochrome P450 (CYP) 3A4 and share the same
etabolic pathway as clopidogrel, have been suggested to
otentially reduce the clinical benefit of clopidogrel (1–4).
owever, there are conflicting opinions on the existence of
clopidogrel–statin interaction. To address this, both pro-
pective studies and post-hoc assessments of large-scale
linical trials have been performed (5–9). In most cases,
owever, as in a post-hoc analysis of the CHARISMA
Clopidogrel for High Atherothrombotic Risk and Ischemic
tabilization, Management, and Avoidance) trial published
n this issue of the Journal (10), no evidence of a negative
linical interaction was shown. In this commentary, we
ddress the current knowledge of ex vivo platelet function
ssessments, as well as clinical studies evaluating the impli-
ations of clopidogrel-statin coadministration.
See page 291
lopidogrel–statin interaction: ex vivo findings and po-
ential clinical implications. Clopidogrel is a prodrug
equiring oxidation by the hepatic CYP system to generate
n active metabolite, which irreversibly blocks the platelet
2Y12 receptor. The degree of metabolic activity of
YP3A4, the dominant metabolic pathway of clopidogrel
11), has been associated with different levels of clopidogrel-
nduced antiplatelet effects (12). Clopidogrel response vari-
bility may be attributed to clinical, cellular, or genetic
actors (1). Some of these can affect the activity of the
YP3A4 system, thus interfering with the hepatic conver-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Division of Cardiology, University of Florida College of Medicine-
acksonville, Jacksonville, Florida; and ‡Interventional Cardiology, San Carlos Uni-m
ersity Hospital, Madrid, Spain. Dr. Angiolillo has served as a consultant/speaker’s
ureau member for Bristol-Myers Squibb and Sanofi-Aventis.ion of clopidogrel into its active metabolite and leading to
ariations in the antiplatelet effects achieved (Table 1).
In 2003, Lau et al. (2) reported an interaction between a
Y3A4 metabolizing statin, atorvastatin, and clopidogrel.
n this preliminary ex vivo study performed in 44 subjects, a
ose-dependent attenuation of clopidogrel-induced anti-
latelet effects was observed. These results rapidly led to
verwhelming concern over the potential harmful conse-
uences of coadministration of these drugs. Results of
nother small ex vivo analysis using another CYP3A4
etabolizing statin (simvastatin) corroborated the presence
f a clopidogrel–statin interaction (3). Despite the ex vivo
ature of these small studies and the lack of evidence of
linical consequences, many patients requiring concomitant
lopidogrel and statin therapy were switched from a
YP3A4-metabolizing to a non–CYP3A4-metabolizing
tatin. This approach also generated dispute, given that
hese findings paralleled in time with the observation that
torvastatin was superior to pravastatin, a non-CYP3A4-
etabolizing statin, in reducing cardiovascular events (13).
n this study, 70% of patients received clopidogrel for at
east 1 month, and, at 30 days, those treated with atorva-
tatin (80 mg) had a 28% relative reduction in the primary
nd point compared with patients treated with pravastatin
40 mg). It would thus be unlikely that these results would
ave been obtained if only patients treated with pravastatin
ere receiving the early benefit of clopidogrel (14).
Recently, there has been accumulating evidence on the
rognostic implications of inadequate clopidogrel-induced
ntiplatelet effects (1). This has inevitably led to further
nvestigation of the clopidogrel–statin interaction phenom-
non. Experimental studies, including several prospective
nalyses and a plethora of post-hoc assessments, mostly
eject the hypothesis of a clopidogrel–statin interaction
1,15). Clinical studies have corroborated these laboratory
ndings (5–8,10). To date, only 1 report showed a negative
linical interaction between clopidogrel and a CYP3A4-
etabolizing statin (9). In addition, this study showed that
ther CYP3A4-metabolized drugs also increased the risk of
dverse cardiac events after stenting (9). These findings
hould not be undervalued, because 50% of all drugs
including many cardiovascular medications) require
YP3A4 (16). However, all other clinical analyses failed to
nd a negative clopidogrel–statin interaction (Table 2).
lopidogrel–statin interaction: insights from the
HARISMA trial. In 2003, Saw et al. (5) demonstrated
he lack of a clopidogrel–statin interaction in a post-hoc
nalysis of the CREDO trial. The unsettled debate on this
otential interaction led the same investigators to perform a
imilar post-hoc analysis in another large-scale, random-
zed, placebo-controlled trial: CHARISMA (10). This
nalysis considered 10,000 patients on the basis of their
aseline use of a statin (65% of the overall study popula-
ion) (10). Of these, 80% were treated with CYP3A4-
etabolizing statins. This is the largest study assessing the
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July 24, 2007:296–8 Editorial Commentheoretical concerns of a clopidogrel–statin interaction in
hich, once more, no interaction was found. Nevertheless,
ome observations from this post-hoc analysis should be
ade.
First, it is important to remember that the primary end
oint of the CHARISMA trial was not met, making this an
verall negative trial (17). Thus, in this setting, it is quite
ifficult to anticipate the identification of any potential
reduction in clinical efficacy” as the result of an interaction
f clopidogrel with another drug. Second, the CHARISMA
rial had a combined primary end point, and data on the
otential influence of statin therapy on each component of
he primary end point would be illustrative. In fact, some
vents (myocardial infarction) may be interpreted as the
esult of increased platelet aggregation, whereas others (fatal
leeding) may have a completely different pathogenesis,
hus canceling the net effects and obscuring the potential
echanisms of Clopidogrel Response Variability
Table 1 Mechanisms of Clopidogrel Response Variability
Clinical factors
Failure to prescribe/poor compliance
Underdosing
Poor absorption
Drug–drug interactions involving intestinal P-glycoprotein (MDR1 gene product)
Drug–drug interactions involving CYP3A4*
Acute coronary syndrome
Diabetes mellitus/insulin resistance
Elevated body mass index
Cellular factors
Accelerated platelet turnover
Reduced CYP3A metabolic activity*
Increased ADP exposure
Up-regulation of the P2Y12 pathway
Up-regulation of the P2Y1 pathway
Up-regulation of P2Y–independent pathways
Genetic factors
Polymorphisms of CYP*
Polymorphisms of GPIa
Polymorphisms of P2Y12
Polymorphisms of GPIIIa
Polymorphisms of MDR1
Factors potentially interfering with hepatic metabolism of clopidogrel.
ADP adenosine diphosphate; CYP cytochrome P450; GP glycoprotein; MDR1multidrug
esistance protein 1.
linical Outcome Studies Evaluating Clopidogrel–Statin Interaction
Table 2 Clinical Outcome Studies Evaluating Clopidogrel–Statin
Study Design
CREDO (5) Post-hoc analysis of a multicenter, randomized, plac
MITRA PLUS (6) Prospective multicenter registry
GRACE (7) Prospective multicenter registry
Mukherjee et al. (8) Prospective single center
Brophy et al. (9) Retrospective analysis of a population-based databa
CHARISMA (10) Post-hoc analysis of a multicenter, randomized, placCS acute coronary syndrome; CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic St
bservation; GRACE  Global Registry of Acute Coronary Events; MITRA PLUS  Maximal Individual Therug interaction. Third, the CHARISMA trial patients
reated with CYP3A4-metabolizing statins had adverse
aseline characteristics (10). However, in the “higher risk”
atient group requiring statins, the primary end point was
ess frequent (5.9% clopidogrel vs. 6.6% placebo) than in the
omplete study cohort (6.8% clopidogrel vs. 7.3% placebo).
his finding appears to be counterintuitive and deserves
urther investigation. Fourth, numerous other cardiovascu-
ar medications are metabolized by the CYP3A4 system and
ay confound this post-hoc assessment (37% of patients
ere receiving calcium antagonists). Finally, more encour-
ging conclusions would come from analyses performed in
he highest risk patients in whom clopidogrel is known to be
articularly effective, such as in the “CAPRIE-like” cohort
f patients enrolled in the CHARISMA trial.
Despite these caveats, overall, the large number of pa-
ients included in the present study, the elegant analysis
erformed, and the consistent results observed in most sub-
roups provide robust evidence excluding any potential clinical
mplication of the disputed clopidogrel–statin interaction.
lopidogrel–statin interaction: a critical appraisal. To
ate, most laboratory findings reject the hypothesis of a
lopidogrel–statin interaction. This inevitably warrants crit-
cal analyses of the studies suggesting the contrary. First,
here are numerous methods to measure clopidogrel-
nduced antiplatelet effects (1). Some of these, however,
uch as light transmittance aggregometry and assessment of
ntraplatelet vasodilator-stimulated phosphoprotein, are
ore validated and have been associated with clinical
utcomes (1). In the few studies demonstrating the presence
f a negative clopidogrel–statin interaction, these method-
logies were not used (2,3). Second, inadequate platelet
nhibition is more common in the early phases of clopi-
ogrel treatment, which is when the studies showing a
egative clopidogrel–statin interaction were performed
2,3). Clopidogrel responsiveness improves with length of
herapy, and there is no evidence that statins negatively
nfluence clopidogrel effects in the steady-state phase of
reatment (1,18). Third, high clopidogrel dosing improves
esponsiveness (1). In studies showing a clopidogrel–statin
nteraction, standard clopidogrel doses were used (2,3).
owever, Lau et al. (2) did observe a dose-dependent effect
raction
Patients
Negative
Clopidogrel–Statin
Interaction
ntrolled trial Nonurgent PCI (n  2,116) No
ACS (n  1,576) No
ACS (n  15,693) No
ACS (n  1,651) No
PCI (n  2,927) Yes
ntrolled trial High-risk for cardiovascular
events (n  15,603)
NoInte
ebo-co
se
ebo-coabilization, Management, and Avoidance; CREDO Clopidogrel for the Reduction of Events During
rapy of Acute Myocardial Infarction PLUS; PCI  percutaneous coronary intervention.
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Editorial Comment July 24, 2007:296–8f CYP3A4-metabolizing statins on clopidogrel-induced
ntiplatelet effects. Alternatively, relatively low doses of
tatins have been used in previous studies. Accordingly, it
emains possible that mild inhibitory effects of atorvastatin
ay have been overlooked by such study designs.
The paucity of evidence supporting a negative clopidogrel–
tatin interaction may question the rationale per se of this
ilemma. Although the CYP3A4 system represents the major
etabolic pathway for clopidogrel (11), other CYP isoenzymes
e.g., 3A5, 2C9, 2C19, 2B6, or 1A2) may be implied (1).
imilarly, metabolism of lipophilic statins also includes auxil-
ary CYP isoenzymes (16). This suggests that alternative CYP
soenzymes may become more relevant in patients concomi-
antly treated with multiple CYP3A4-metabolized drugs.
oreover, it cannot be excluded that a clopidogrel–statin
nteraction may be observed only in specific patient subgroups,
uch as those with low CYP3A4 metabolic activity (12) or with
p-regulation of the P2Y12 pathway (19). Genetic profiling
nd studies in specific patient subsets may be useful to unravel
his dilemma. Ultimately, the presence of an extrahepatic
rigin of a clopidogrel–statin interaction should not be under-
stimated. In fact, CYP3A4-metabolizing statins have inhib-
tory effects on the multidrug transporter P-glycoprotein lo-
ated on intestinal epithelial cells, and recent findings have
hown that clopidogrel absorption and active metabolite for-
ation are diminished by P-glycoprotein mediated efflux
16,20).
onclusions
ata currently available suggest that clopidogrel response
ariability is clinically more important than the possibility of
nteraction with other CYP3A4-metabolized drugs. There-
ore, clinicians should continue to prescribe clopidogrel and
tatins where clinically indicated and disregard selecting
tatins on the basis of CYP3A4 metabolism. Nevertheless,
rospective studies are still required to fully elucidate the
otential clinical impact of coadministration of CYP3A4-
etabolized drugs, including clopidogrel and lipophilic
tatins. Patients in whom these drugs have clearly proven to
e clinically effective should be targeted for these studies,
hich should be integrated with standardized biological
ssessments. With the ever-increasing length of dual anti-
latelet therapy required after the use of drug-eluting stents
21), any potential drug interaction with clopidogrel war-
ants further investigation. Given the widespread use of
hese medications in patients with cardiovascular disease,
ven a significantly marginal effect may be extremely far
eaching, translating into a large number of clinical events in
outine clinical practice.
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